- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens Healthineers Showcase New PET/CT Scanner at SNMMI
A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
Biograph Vision.X (Image Credit: Seimens Healthineers)
Offering technological advancements ranging from an accelerated time of flight (TOF) to artificial intelligence (AI)-enabled workflow enhancements, Siemens Healthineers showcased Biograph Vision.X, a new positron emission tomography/computed tomography (PET/CT) system at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27 in Chicago.
One of the new system’s benefits is the Optiso Ultra Dynamic Range detector technology, which reportedly provides enhanced spatial resolution through silicon photomultipliers (SiPMs) that facilitate utilization of small (3.2 mm x 3.2 mm) lutetium oxyorthosilicate crystal elements.
Leveraging this technology, the Biograph Vision.X also offers a TOF of 178 picoseconds that bolsters patient throughput and reduces radiation exposure for patients, according to Siemens Healthineers.
“This TOF improvement translates into true increased sensitivity for better imaging performance. This level of precision is more important than ever as more physicians now use PET/CT imaging not only for diagnosis but throughout the patient care cycle – from diagnosis to therapy monitoring to post-therapy follow up,” noted James Williams, Ph.D, the head of Siemens Healthineers Molecular Imaging. “And such precision in PET/CT is invaluable in theranostics, where diagnostic and therapeutic capabilities are combined to help treat post-recurrent prostate cancer patients.”
The company added that the system leverages AIDAN intelligent imaging, an AI platform built on over 700 patented machine- and deep learning applications, to enhance radiology workflow efficiency.
Pending 510(k) clearance from the Food and Drug Administration, the Biograph Vision.X system is not commercially available at this time, according to Siemens Heathineers. The company said the new system will be available as in-field upgrade for physicians who currently utilize the Biograph Vision device.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
